創耀科技(688259.SH):局端芯片目前已試產完成
格隆匯4月28日丨有投資者在投資者互動平台向創耀科技(688259.SH)提問,“公司之前預期局端芯片Q1可以出貨,現在有進展了嗎?”
創耀科技回覆稱,公司局端芯片目前已試產完成,局端芯片在試驗局完成測試後,公司將成為除某行業頭部通信半導體設計公司外唯一具備局端芯片設計能力的公司,局端芯片產品有望進入歐洲市場與國際半導體設計企業同類產品同台競爭。客户目前局端芯片庫存還未消耗完,等庫存消化後會逐步採購公司相關產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.